In current clinical practice, multigene-based expression assays, such as the 70-gene expression profile and the 21-gene recurrence score, are currently being used to predict the likelihood of recurrence in patient subsets who have had hormone receptor–positive, ERBB2-negative early-stage breast tumors.5,6 It is suggested that the combination of radiomics and genomics might better guide clinical decision-making. Here, NR4A1 is linked to breast neoplasm.